What is a stock summary page? Click here for an overview.
Business Description
Geovax Labs Inc
NAICS : 325412
SIC : 2834
ISIN : US3736782000
Description
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 38.78 | |||||
| Equity-to-Asset | 0.62 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -28.44 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -7 | |||||
| 3-Year EBITDA Growth Rate | 52.8 | |||||
| 3-Year EPS without NRI Growth Rate | 52.9 | |||||
| 3-Year FCF Growth Rate | 44.4 | |||||
| 3-Year Book Growth Rate | -64 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 251.44 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.19 | |||||
| 9-Day RSI | 49.41 | |||||
| 14-Day RSI | 44.41 | |||||
| 3-1 Month Momentum % | -33.82 | |||||
| 6-1 Month Momentum % | -33.82 | |||||
| 12-1 Month Momentum % | -6.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.55 | |||||
| Quick Ratio | 2.55 | |||||
| Cash Ratio | 1.77 | |||||
| Days Sales Outstanding | 39.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -191.6 | |||||
| Shareholder Yield % | -154.62 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -635.91 | |||||
| Net Margin % | -632.07 | |||||
| FCF Margin % | -624.08 | |||||
| ROE % | -732.43 | |||||
| ROA % | -347.07 | |||||
| ROIC % | -4571.64 | |||||
| 3-Year ROIIC % | -12071.7 | |||||
| ROC (Joel Greenblatt) % | -14000 | |||||
| ROCE % | -732.78 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.56 | |||||
| PB Ratio | 2.04 | |||||
| Price-to-Tangible-Book | 2.08 | |||||
| EV-to-EBIT | -0.5 | |||||
| EV-to-Forward-EBIT | -0.89 | |||||
| EV-to-EBITDA | -0.5 | |||||
| EV-to-Forward-EBITDA | 0.13 | |||||
| EV-to-Revenue | 3.14 | |||||
| EV-to-Forward-Revenue | 7.33 | |||||
| EV-to-FCF | -0.5 | |||||
| Price-to-Net-Current-Asset-Value | 2.12 | |||||
| Price-to-Net-Cash | 4.25 | |||||
| Earnings Yield (Greenblatt) % | -200 | |||||
| FCF Yield % | -182.54 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GOVX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Geovax Labs Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3.954 | ||
| EPS (TTM) ($) | -6.154 | ||
| Beta | 4.33 | ||
| 3-Year Sharpe Ratio | 0.11 | ||
| 3-Year Sortino Ratio | 0.26 | ||
| Volatility % | 178.14 | ||
| 14-Day RSI | 44.41 | ||
| 14-Day ATR ($) | 0.142354 | ||
| 20-Day SMA ($) | 0.9769 | ||
| 12-1 Month Momentum % | -6.8 | ||
| 52-Week Range ($) | 0.73 - 11.18 | ||
| Shares Outstanding (Mil) | 13.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Geovax Labs Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Geovax Labs Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Geovax Labs Inc Frequently Asked Questions
What is Geovax Labs Inc(GOVX)'s stock price today?
The current price of GOVX is $0.98. The 52 week high of GOVX is $11.18 and 52 week low is $0.73.
When is next earnings date of Geovax Labs Inc(GOVX)?
The next earnings date of Geovax Labs Inc(GOVX) is .
Does Geovax Labs Inc(GOVX) pay dividends? If so, how much?
Geovax Labs Inc(GOVX) does not pay dividend.
Guru Commentaries on NAS:GOVX
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers